ProKidney Corp. Class A PROK 深 滬
交易中 05-11 12:12:26 美东时间
1.815
-0.045
-2.42%
華盛通- 最 高1.93
- 今 開1.88
- 成交量 70.87万股
- 最 低 1.815
- 昨 收 1.86
- 總市值 5.48亿
- 52周最高 7.13
- 市盈率 靜 --
- 換手率 0.23%
- 52周最低 0.54
- 委 比 52.81%
- 總股本 3.02亿
- 歷史最高 14.19
- 量 比 2.99
- 振 幅 6.18%
- 歷史最低 0.4603
- 每 手 1
- 風險率 0.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
ProKidney Corp. has appointed Greg Madison as Chief Commercial Officer to lead the commercialization of rilparencel, a cell therapy for chronic kidney disease (CKD) and diabetes. Madison brings over two decades of experience in biopharma, including successful drug launches and business development. He joins ProKidney during a critical phase as the company advances rilparencel toward potential commercialization. Rilparencel aims to address unmet n...
03-25 20:01
ProKidney Q4 EPS $(0.14) Misses $(0.11) Estimate, Sales $225.000K Beat $83.333K Estimate
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 23.89 percent. This is a 12.5 percent increase over losses of $(0.16) per share from the
03-19 04:06
ProKidney Advances Rilparencel Program and Manufacturing Expansion
An announcement from ProKidney ( ($PROK) ) is now available. ProKidney has upda...
01-12 21:49
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
ProKidney Corp.'s CEO, Bruce Culleton, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company's lead product, rilparencel, is in a Phase 3 study for chronic kidney disease and Type 2 diabetes. A live webcast and 30-day replay will be available on ProKidney's website.
01-06 12:30
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
Issued on behalf of Avant Technologies Inc. Equity Insider News Commentary VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- The cell therapy manufacturing sector reached a pivotal inflection poi...
2025-12-17 00:53
HC Wainwright & Co. Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $12
HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on ProKidney (NASDAQ:PROK) with a Buy rating and announces Price Target of $12.
2025-12-16 20:03
ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 13.04 percent. This is a 14.29 percent increase over losses of $(0.14) per share from the
2025-11-11 05:36
Cell therapy firm ProKidney's Q3 net loss narrows
Overview ProKidney ended Q3 2025 with $272 mln in cash, supporting operations into mid-2027 Outlook Company expects cash to support operations into mid-2027 Result Drivers R&D EXPENSES - Decrease in R...
2025-11-11 05:33
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
A Phase 2 REGEN-007 trial demonstrated that rilparencel, a cell therapy, significantly slowed chronic kidney disease (CKD) progression in diabetic patients. Group 1 showed a 78% improvement in eGFR slope, with no serious adverse events. Phase 3 PROACT 1, which uses eGFR slope as a surrogate endpoint, has enrolled over half its required participants, with topline results expected in Q2 2027. Rilparencel is the first cell therapy in a Phase 3 trial...
2025-11-06 16:00
